Compare Gilead Sciences, Inc. (GILD) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Skyworks Solutions Inc — how do they compare? Gilead Sciences, Inc. trades at $151.13 (market cap $182.40B), while Skyworks Solutions Inc trades at $76.65 (market cap $12.15B). The key difference: Gilead Sciences, Inc. is far larger — about 15× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays the higher dividend (4.13%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Skyworks Solutions Inc for 50 Days on average.
| GILD | SWKS | |
|---|---|---|
Market Cap | $182.40B | $12.15B |
Volume | 4,469,821 | 7,390,810 |
Sector | Health | Technology |
52-Week High | $155.80 | $91.45 |
52-Week Low | $116.74 | $52.50 |
Typical Hold Time | 111 Days | 50 Days |
Enterprise Value | $205.46B | $12.03B |
Dividend Yield | 2.23% | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
Skyworks Solutions (SWKS) trades at $76.35, down 8.49% in the last session, reflecting near-term pressure despite beating earnings estimates in recent quarters. The stock exhibits a bearish technical signal, with key support at $76, while fundamentals show declining revenue and net income margins over recent years. The pending merger with Qorvo represents a significant strategic development, aimed at enhancing scale and market diversification.
The investment outlook is mixed, with analyst consensus leaning bullish (60% buy ratings) and a price target of $78.80 offering modest upside. However, risks include execution challenges from the merger, competitive pressures in semiconductors, and ongoing profitability declines. The stock's current valuation at a P/E of 41.84 appears elevated relative to earnings growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
